GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » Beginning Cash Position

Apollomics (Apollomics) Beginning Cash Position : $25.28 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Apollomics Beginning Cash Position?

Apollomics's Beginning Cash Position for the quarter that ended in Dec. 2023 was $25.28 Mil.

Apollomics's quarterly Beginning Cash Position declined from Dec. 2022 ($50.70 Mil) to Jun. 2023 ($32.68 Mil) and declined from Jun. 2023 ($32.68 Mil) to Dec. 2023 ($25.28 Mil).

Apollomics's annual Beginning Cash Position declined from Dec. 2021 ($130.65 Mil) to Dec. 2022 ($46.74 Mil) and declined from Dec. 2022 ($46.74 Mil) to Dec. 2023 ($32.68 Mil).


Apollomics Beginning Cash Position Historical Data

The historical data trend for Apollomics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Beginning Cash Position Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Beginning Cash Position
38.49 130.65 46.74 32.68

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beginning Cash Position Get a 7-Day Free Trial 59.61 46.74 50.70 32.68 25.28

Apollomics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


Apollomics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Apollomics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollomics (Apollomics) Business Description

Traded in Other Exchanges
Address
989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an innovative clinical-stage biotechnology company. It is is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. It has a pipeline of 9 drug candidates across multiple programs, 6 of which are in the clinical stage of development.